258 related articles for article (PubMed ID: 30996138)
1. Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody.
Makita N; Ando T; Sato J; Manaka K; Mitani K; Kikuchi Y; Niwa T; Ootaki M; Takeba Y; Matsumoto N; Kawakami A; Ogawa T; Nangaku M; Iiri T
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996138
[TBL] [Abstract][Full Text] [Related]
2. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations.
Makita N; Sato J; Manaka K; Shoji Y; Oishi A; Hashimoto M; Fujita T; Iiri T
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5443-8. PubMed ID: 17372216
[TBL] [Abstract][Full Text] [Related]
3. Successful prednisolone or calcimimetic treatment of acquired hypocalciuric hypercalcemia caused by biased allosteric CaSR autoantibodies.
Makita N; Sato J; Manaka K; Akahane K; Ito T; Yamazaki H; Mizoguchi A; Hikima Y; Horikoshi H; Nangaku M; Iiri T
JCI Insight; 2022 Oct; 7(20):. PubMed ID: 36099030
[TBL] [Abstract][Full Text] [Related]
4. Biased agonism: a novel paradigm in G protein-coupled receptor signaling observed in acquired hypocalciuric hypercalcemia.
Makita N; Iiri T
Endocr J; 2014; 61(4):303-9. PubMed ID: 24240576
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor.
Pallais JC; Kemp EH; Bergwitz C; Kantham L; Slovik DM; Weetman AP; Brown EM
J Clin Endocrinol Metab; 2011 Mar; 96(3):672-80. PubMed ID: 21159843
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune Hypercalcemia Due to Autoantibodies Against the Calcium-sensing Receptor.
Miñambres I; Corcoy R; Weetman AP; Kemp EH
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32311038
[TBL] [Abstract][Full Text] [Related]
7. Personalised medicines for familial hypercalcemia and hyperparathyroidism.
Josephs TM; Zhang F; Dinh LV; Keller AN; Conigrave AD; Capuano B; Gregory KJ; Leach K
J Mol Endocrinol; 2022 May; 69(1):243-257. PubMed ID: 35318962
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.
Babinsky VN; Hannan FM; Gorvin CM; Howles SA; Nesbit MA; Rust N; Hanyaloglu AC; Hu J; Spiegel AM; Thakker RV
J Biol Chem; 2016 May; 291(20):10876-85. PubMed ID: 26994139
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.
Koca SB
Turk J Pediatr; 2023; 65(5):853-861. PubMed ID: 37853976
[TBL] [Abstract][Full Text] [Related]
10. Acquired hypocalciuric hypercalcemia in a patient with CKD.
Kuo E; Kemp EH; Sandhu HK; Brown EM; Weetman AP; Huang CL
Am J Kidney Dis; 2013 Dec; 62(6):1151-4. PubMed ID: 23810542
[TBL] [Abstract][Full Text] [Related]
11. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
Davey AE; Leach K; Valant C; Conigrave AD; Sexton PM; Christopoulos A
Endocrinology; 2012 Mar; 153(3):1232-41. PubMed ID: 22210744
[TBL] [Abstract][Full Text] [Related]
12. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of hypercalcemia by cinacalcet treatment in a subject with relapsing acquired hypocalciuric hypercalcemia: A case report.
Sanada J; Kamei S; Shimoda M; Tatsumi F; Kimura T; Obata A; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Medicine (Baltimore); 2021 Oct; 100(42):e27579. PubMed ID: 34678905
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation.
Howles SA; Hannan FM; Gorvin CM; Piret SE; Paudyal A; Stewart M; Hough TA; Nesbit MA; Wells S; Brown SD; Cox RD; Thakker RV
JCI Insight; 2017 Oct; 2(20):. PubMed ID: 29046478
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator].
Nagano N; Tsutsui T
Clin Calcium; 2016 Jun; 26(6):839-50. PubMed ID: 27230839
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα
Gorvin CM; Hannan FM; Cranston T; Valta H; Makitie O; Schalin-Jantti C; Thakker RV
J Bone Miner Res; 2018 Jan; 33(1):32-41. PubMed ID: 28833550
[TBL] [Abstract][Full Text] [Related]
17. [Case report; A case of acquired hypocalciuric hypercalcemia due to autoantibody against the calcium-sensing receptor].
Seino A; Iguchi A; Ito T; Saeki T; Makita N; Iiri T; Yamazaki H
Nihon Naika Gakkai Zasshi; 2014 May; 103(5):1180-2. PubMed ID: 25026789
[No Abstract] [Full Text] [Related]
18. Mapping of human autoantibody binding sites on the calcium-sensing receptor.
Kemp EH; Gavalas NG; Akhtar S; Krohn KJ; Pallais JC; Brown EM; Watson PF; Weetman AP
J Bone Miner Res; 2010 Jan; 25(1):132-40. PubMed ID: 19580466
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-responsive lymphocytic parathyroiditis and hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor: a case report and literature review.
Song L; Liu L; Miller RT; Yan SX; Jackson N; Holt SA; Maalouf NM
Eur J Endocrinol; 2017 Jul; 177(1):K1-K6. PubMed ID: 28515208
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1.
Cuny T; Romanet P; Goldsworthy M; Guérin C; Wilkin M; Roche P; Sebag F; van Summeren LE; Stevenson M; Howles SA; Deharo JC; Thakker RV; Taïeb D
J Clin Endocrinol Metab; 2024 Jan; 109(2):549-556. PubMed ID: 37602721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
